Double-blind evaluation of deanol in tardive dyskinesia.

Abstract

We administered deanol acetamidobenzoate, 2.0 g/day for four weeks, a double-blind, placebo-controlled crossover trial, to 14 patients with tardive dyskineasia. The patient population included both inpatients and outpatients. The response was evaluated by subjective clinical impression and scoring of filmed sequences. Patients' conditions improved significantly from baseline scores while receiving both deanol and placebo, but there was no distinction between the two treatments.

• Authors: P Penovich, J P Morgan, B Kerzner, F Karch, D Goldblatt
• Journal: JAMA (JAMA) Vol. 239 Issue 19 Pg. 1997-8 (May 12 1978) ISSN: 0098-7484 [Print] United States
• PMID: 347112 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Ethanolamines
• Deanol

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Deanol (administration & dosage, therapeutic use)
• Double-Blind Method
• Drug Evaluation
• Dyskinesia, Drug-Induced (drug therapy)
• Ethanolamines (therapeutic use)
• Female
• Humans
• Male
• Middle Aged